EMSAM Drug Patent Profile
✉ Email this page to a colleague
When do Emsam patents expire, and when can generic versions of Emsam launch?
Emsam is a drug marketed by Somerset and is included in one NDA.
The generic ingredient in EMSAM is selegiline. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selegiline profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMSAM?
- What are the global sales for EMSAM?
- What is Average Wholesale Price for EMSAM?
Summary for EMSAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Patent Applications: | 4,540 |
| Drug Prices: | Drug price information for EMSAM |
| What excipients (inactive ingredients) are in EMSAM? | EMSAM excipients list |
| DailyMed Link: | EMSAM at DailyMed |
Pharmacology for EMSAM
| Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
| Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |
US Patents and Regulatory Information for EMSAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-001 | Feb 27, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-002 | Feb 27, 2006 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-003 | Feb 27, 2006 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EMSAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-003 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-001 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-001 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-002 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-002 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336-002 | Feb 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EMSAM
See the table below for patents covering EMSAM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 628340 | ⤷ Sign Up | |
| Canada | 1329132 | METHODE D'ADMINISTRATION DU DEPRENYL, PERMETTANT DE REDUIRE AU MINIMUM LES EFFETS SECONDAIRES DU PRODUIT (METHOD FOR ADMINISTERING THE DRUG DEPRENYL SO AS TO MINIMIZETHE DANGER OF SIDE EFFECTS) | ⤷ Sign Up |
| Australia | 3502289 | ⤷ Sign Up | |
| China | 1038385 | ⤷ Sign Up | |
| China | 1048320 | ⤷ Sign Up | |
| European Patent Office | 1561461 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
